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Cell surface heparan sulfate proteoglycans (HSPGs) mediate internalization of HIV-1 Tat. Herein, we report that human WiDr cells, which
express perlecan but no other HSPGs, can internalize 125I-labeled Tat with minimal lysosomal degradation. Pre-treatment of cells with
heparitinase almost completely abolished 125I-Tat surface binding, while the use of an HIV-1 long terminal repeat (LTR) promoter–reporter
construct demonstrated that transactivation was potently blocked by pretreatment of cells with heparitinase, indicating an essential role for
perlecan in the biologic effects of Tat. We conclude that the perlecan mediates Tat uptake and is required for HIV-1 LTR-directed
transactivation in this human cell type.
D 2004 Elsevier Inc. All rights reserved.
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The Tat protein of human immunodeficiency virus type I
(HIV-1) is a potent transcriptional transactivator of the
integrated viral genome (Berkhout et al., 1989; Frankel and
Young, 1998; Sodroski et al., 1985). It can be released from0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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Philadelphia, PA 19118, United States.productively infected cells and internalized by a wide
variety of cell types (Ensoli et al., 1993; Frankel and Pabo,
1988; Green and Loewenstein, 1988; Mann and Frankel,
1991). Tyagi et al. (2001) have recently reported that
HSPGs are important for Tat internalization and subsequent
HIV-1-directed LTR transactivation. Thus, soluble heparin
or treatment of cells with glycosaminoglycan lyases inhibit
the uptake of extracellular Tat and its HIV-1 LTR trans-
activating activity (Tyagi et al., 2001). Nevertheless, HSPGs
are a highly diverse group of molecules that include three
major classes: the transmembrane syndecan family; the
phosphatidylinositol-anchored glypican family; and perle-
can (Fuki et al., 1997, 2000; Williams and Fuki, 1997). Of
particular interest is the perlecan HSPG, a completely
extracellular molecule that is present on cell surfaces and
in the extracellular matrix. We have shown that perlecan
mediates an unusual internalization pathway that transports
ligands into the cell, but then is remarkably inefficient at
delivering its ligands into lysosomes for degradation (Fuki04) 481–486
Rapid Communication482et al., 2000). Perlecan is produced by at least one cell type
that is permissive for HIV-1 infection (Miller et al., 1997),
and it is highly expressed by endothelial cells, an important
secondary target of HIV-1 infection in the central nervous
system (Argyris et al., 2003). Perlecan can also be
transferred from cells synthesizing this HS proteoglycan to
other cells in the microenvironment (Fuki et al., 2000).
Therefore, we hypothesized that perlecan is an attractive
candidate for biologically important HIV-1 Tat internal-
ization, because it should allow intracellular persistence of
Tat, thereby facilitating gene transactivation. Using a human
cell, WiDr, that expresses perlecan but lacks all other
proteoglycans (Iozzo, 1984), we found that perlecan
contributes to surface binding and internalization of Tat,
but that essentially all Tat-mediated transactivation
depended on perlecan in this system. These findings are
the first identification of a specific HSPG, perlecan, that
participates in HIV-1 Tat catabolism and biological activity.Fig. 1. Involvement of the perlecan HSPG in uptake and catabolism of
extracellular 125I-Tat. WiDr cells were pre-treated without () or with (+)
5.5 U/ml heparitinase, followed by incubation with 125I-Tat (1 Ag/ml) for 5
h (A) or 21 h (B). Displayed are means F SEM, n = 3, for surface-bound,
internalized, and degraded 125I-Tat. The graphs represent the mean values
of two independent experiments, each conducted in triplicate.Results and discussion
Involvement of perlecan HSPG in cellular binding,
internalization, and degradation of HIV-1 Tat
To examine whether the HSPG perlecan is able to
mediate cellular uptake and catabolism of extracellular Tat,
we incubated WiDr cells with 125I-Tat. As shown in Fig. 1A,
after a 5-h incubation, substantial quantities of 125I-Tat were
bound to the cell surface and internalized by WiDr cells,
while only a small fraction was degraded, consistent with
the perlecan endocytic pathway (Fuki et al., 2000). Pre-
treatment of the cells with heparitinase resulted in a near-
total inhibition of 125I-Tat surface binding (by 94.2%, P b
0.00005), and significantly reduced Tat internalization (37%
inhibition; P b 0.005), but did not affect Tat degradation
over this period (Fig. 1A). In control experiments using a
ligand, LpL-enriched 125I-mLDL, that binds HS but no
other known receptors on WiDr cells, we verified our
previous finding (Fuki et al., 2000) that heparitinase
essentially completely blocked its binding and internal-
ization, indicating efficient, functional destruction of perle-
can HSPG (96 F 3.1% and 87 F 2.8% inhibition,
respectively). After 21 h of incubation, WiDr cells inter-
nalized higher amounts of 125I-Tat, as compared to the 5-h
incubation, but still only a small fraction of the ligand was
degraded (Fig. 1B). Similar to the 5-h results, pre-treatment
of the cells with heparitinase had a profound inhibitory
effect on 125I-Tat binding by 97%, and inhibited internal-
ization by 40%, while degradation was not affected. These
findings demonstrate that the perlecan HSPG can mediate
Tat binding and uptake, but with little participation in the
delivery of Tat to lysosomes. The residual internalization of
Tat in cells pre-treated with heparitinase, at both 5- and 21-h
incubation periods, also indicates the existence of HSPG-
independent mechanisms(s) (Silhol et al., 2002). Unlikeperlecan, the HSPG-independent mechanisms mediate
internalization without a large amount of cell surface
accumulation, suggesting more rapid endocytosis (Goldstein
et al., 1983).
Effects of inhibitors on HIV-1 Tat binding and
internalization
To further explore Tat catabolism, we pre-treated WiDr
cells with different inhibitors followed by incubation with
125I-Tat. As shown in Figs. 2A and B, pre-treatment of cells
with 100 Ag heparin/ml substantially blocked both binding
and internalization of 125I-Tat (nearly 100% inhibition).
Heparin is a close structural homologue of the HS glycosQ
Fig. 2. Effects of inhibitors on uptake and catabolism of extracellular
125I-Tat. WiDr cells were untreated (no inhibitor) or pre-treated with
heparin (100 Ag/ml) or cytochalasin D (5 AM), as indicated, followed by
incubation with 125I-Tat (1 Ag/ml) for 5 h (A) or 21 h (B). Displayed
are means F SEM, n = 3, for surface-bound, internalized, and degraded
125I-Tat. The graphs represent the mean values of two independent
experiments, each conducted in triplicate.
Rapid Communication 483aminoglycan, and has been used to compete with the
binding of positively charged ligands to HS and other cell
surface molecules (Fuki et al., 1997; Tyagi et al., 2001;
Williams et al., 1992). Pre-treatment of cells with eitherheparitinase (Fig. 1) or a low concentration of heparin
(Fig. 2) had a strong inhibitory effect on Tat binding, while
internalization was not altered to the same extent by the two
reagents. These results indicate that a low concentration of
heparin competes for Tat binding not only to HS, but also to a
subset of non-HSPG receptors responsible for the HS-
independent component of Tat internalization, as demon-
strated in Fig. 1 (Fuki et al., 1997; Williams et al., 1992).
In addition, as shown in Figs. 2A and B, we also
investigated the effects of cytochalasin D on Tat catabolism.
Cytochalasin D, which represents an F actin elongation
inhibitor that disrupts the cytoskeleton, strongly inhibited Tat
internalization at both the 5- and 21-h time points. Recent
reports on the effect of cytochalasin D on Tat internalization
have demonstrated similar results, thus implicating a key
role for the cytoskeleton (Ferrari et al., 2003).
Crucial role of perlecan in HIV-1 LTR-directed
transactivation
To determine the ability of the perlecan HSPG to
participate in gene transactivation by exogenous Tat, we
stably transfected WiDr cells with an HIV-1 LTR-EGFP
construct, followed by incubations with exogenously added
HIV-1 Tat for 5 and 21 h. As illustrated in Figs. 3A–C,
WiDr cells treated with 1 Ag of extracellular Tat/ml showed
significant LTR transactivation after 5 h (Fig. 3B), with
higher levels after a 21-h incubation period (Fig. 3C). This
time course is similar to our findings on Tat uptake and
internalization, and is somewhat slower than results reported
from other cell systems (Tyagi et al., 2001). Most
importantly, pre-treatment of HIV-1 LTR-EGFP transfected
WiDr cells with heparitinase nearly completely abolished
the transactivation activity of extracellular Tat (Figs.
3D,E,H). These data indicate an essential role for the
perlecan HSPG in HIV-1 Tat uptake and biologic action in
these cells. In addition, cytochalasin D strongly inhibited
gene transactivation, as shown in Figs. 3F–H, consistent
with its ability to block internalization.
Overall, our results demonstrate that a specific HSPG,
perlecan, can mediate HIV-1 Tat binding and internalization,
leading to gene transactivation. The process depends on
perlecan heparan sulfate side chains, which mediate Tat
binding, and on the cytoskeleton, which participates in HIV-
1 Tat trafficking. Our findings also indicate the existence of
HSPG-independent mechanism(s) (Silhol et al., 2002) for
Tat catabolism in WiDr cells, but these appear to have a far
less efficient role in HIV-1 LTR transactivation. Our data do
not exclude a possible role for other HSPGs, such as
syndecans or glypicans, in Tat catabolism, or biologic
activity in different experimental systems, although the
efficient delivery of syndecan ligands to lysosomes (Fuki
et al., 1997; Williams and Fuki, 1997) may not allow
subsequent gene transactivation. In addition, our findings
exclude Tat uptake by a mechanism that does not require
surface receptor-binding (such as pinocytosis), as demon-
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(100 Ag/ml) on both Tat-binding and internalization (Fig. 2).
A number of cell types targeted by HIV-1 have been
shown to synthesize and express perlecan. Perlecan is
produced by at least some cell types, brain microglia/
macrophages, which are permissive for HIV-1 infection and
represent important HIV-1 reservoirs in vivo (Miller et al.,
1997). In addition, perlecan is highly expressed by
endothelial cells, a key secondary target of HIV-1 infection
(Argyris et al., 2003), and by epithelial cells (Williams and
Fuki, 1997). Perlecan can also be transferred from a cell that
secretes it, to other cells, where it mediates its unusual
uptake pathway (Fuki et al., 2000). Therefore, the inter-
actions between HIV-1 Tat and the perlecan HSPG are likely
to contribute to the HIV-1 life cycle and HIV-1-induced
pathogenesis, plus potentially neuropathogenesis, and con-
stitute a novel important target for potential therapeutic
interventions.Materials and methods
Reagents
Unless otherwise indicated, chemicals were purchased
from Sigma Inc. (St. Louis, MO). Recombinant HIV-1 Tat
protein (86 amino acids) was obtained from the NIH AIDS
Research and Reference Reagent Program (Rockville, MD)
and from Fitzgerald Industries International, Inc. (Concord,
MA). For each experiment, recombinant Tat (50 Ag) was
labeled with carrier-free 125I (NEN Life Sciences) using
iodogen-coated tubes (Pierce, Rockford, IL). Bovine milk
lipoprotein lipase (LpL) and 125I-labeled methylated human
plasma low-density lipoprotein (125I-mLDL), which served
as controls in our studies, were prepared as described
previously (Fuki et al., 1997, 2000).
Cell cultures
In our studies, we employed the human colon carcinoma
cell line, WiDr (ATCC no. CCL-218), which synthesizes
perlecan but no other HSPGs (Dodge et al., 1990; Fuki et
al., 2000; Iozzo, 1984). WiDr cells were cultured in
Dulbecco’s modified Eagle’s medium supplemented with
10% fetal bovine serum.
Cellular uptake and degradation of 125I-labelled HIV-1 Tat
WiDr cells were grown in 12-well plates to approx-
imately 80% confluence and then incubated with aliquots ofig. 3. Molecular participants in the transactivating activity of extracellular HIV-1 Tat. WiDr cells, stably transfected with the HIV-1 LTR promoter/EGFP
eporter construct, were incubated without Tat (A) or with 1 Ag of exogenously added Tat /ml (B–G). Results from 5-h incubations are shown in the left-hand
anels (B, D, F), and 21-h data are shown in the right-hand panels (C, E, G). Before incubation with extracellular Tat, cells were untreated (B, C), or pre-treated
ith 5.5 U heparitinase/ml (D, E), or 5 AM cytochalasin D (F, G). Gene transactivation and EGFP expression are displayed as fluorescent microscopic images
A–G), and semiquantitatively (H). The graphs represent the mean values of three independent experiments.F
r
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(125I-labelled HIV-1 Tat (1 Ag/ml) in serum-free media at
37 8C for 5 or 21 h. Cellular uptake and degradation of 125I-
Tat were analyzed by quantitation of surface-bound (i.e.,
releasable by a high concentration of heparin, 10 mg/ml,
added after the 5- or 21-h incubation), intracellular (heparin-
resistant), and lysosomally degraded material (assessed by
trichloroacetic acid-soluble, CHCl3-insoluble radioactivity
in media), as described (Goldstein et al., 1983). As
previously (Fuki et al., 2000), to assess the efficiency of
endocytosis, we calculated ligand internalization as the sum
of intracellular accumulation plus degradation. To examine
the role of the heparan sulfate side chains of perlecan in
binding and catabolism of 125I-Tat, WiDr cells were pre-
treated for 1 h with heparitinase (5.5 units/ml) or a low
concentration of heparin (100 Ag/ml) in serum-free medium,
and these reagents were kept continuously present after
addition of 125I-Tat, as described previously (Fuki et al.,
1997, 2000; Williams et al., 1992), to prevent reassembly or
function of HS side chains. To examine intracellular
processes involved in Tat catabolism via the perlecan HSPG,
we incubated WiDr cells with 125I-Tat in the presence of
cytochalasin D (0–5 AM), which disrupts the cytoskeleton
and can inhibit uptake via perlecan (Fuki et al., 2000). As
controls, we also assayed the catabolism of a ligand, LpL-
enriched 125I-mLDL, that we showed previously to be
internalized via perlecan in this cell type (Fuki et al.,
2000). All samples were normalized to total cell protein,
which were assayed by the modified Lowry method (Sigma).
HIV-1 LTR-directed transactivation in WiDr cells
We constructed an HIV-1 LTR promoter/enhanced green
fluorescence protein (EGFP) reporter plasmid and estab-
lished a WiDr cell line stably expressing this construct. The
enhanced green fluorescent protein expression plasmid
(pEGFP-C1) from Clontech (Palo Alto, CA.) was digested
with the restriction enzymes, Ase1 and Nhe1, which
removed the CMV promoter. DNA encoding the HIV-1
LTR, from the viral strain, NL4-3, was polymerase chain
reaction (PCR) amplified using 5V and 3V primers incorpo-
rating Ase1 and Nhe1 sites, respectively, and the PCR
product was ligated into the digested pEGFP plasmid. The
resultant HIV-1 LTR-EGFP plasmid was linearized with
Stu1 and transfected into the WiDr human colon carcinoma
cell line using the Profection mammalian transfection kit
from Promega (Madison, WI). Stable transfectants express-
ing EGFP were selected by increasing addition of G418
from 200 to 600 Ag/ml over a period of approximately 3
weeks. G418-resistant cells were isolated by overlaying
individual colonies with sterile Whatman paper disks
Rapid Communication486soaked in 0.25% trypsin, 1 mM EDTA. Cells adhering to the
paper disks were place in fresh culture media containing 600
Ag G418/ml and expanded. Clonal cells were viewed under
a fluorescence microscope at 495-nm emission to select for
stable transfectants expressing EGFP. LTR-EGFP-stably
transfected WiDr cells, untreated or pretreated for 1 h with
heparitinase (5.5 U/ml) and/or other inhibitors, were
incubated with exogenously added HIV-1 Tat (1 Ag/ml)
for 5 or 21 h. As before, inhibitors were kept continuously
present in the media after addition of 125I-Tat to prevent
reassembly or function of HS side chains. Gene trans-
activation was assessed by fluorescence microscopy and
determined semiquantitatively, as described previously
(Acheampong et al., 2002).
Statistical analysis
Unless otherwise indicated, results are provided as
means F SE (n = 3). For statistical comparisons between
two groups, the unpaired two-tailed Student’s t test was
used. For three or more groups, ANOVA was employed,
followed by post hoc multiple pairwise comparisons by the
Student–Newman–Keuls test (Fuki et al., 1997).Acknowledgments
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